REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2024.
Recent Highlights
“Our customers have made important progress in validating the differentiated value of deep, unbiased proteomics at scale throughout the year, and I’m thrilled that the momentum is growing despite the challenging macroeconomic environment” said Omid Farokhzad, Chair and CEO of Seer. “We saw a surge in customer publications, strong demand for STAC, and we expanded upon our partnership with Thermo Fisher Scientific to accelerate adoption of our Proteograph Product Suite. I believe we are well-positioned for a stronger year in 2025 and my confidence in our platform, our value proposition, and the immense opportunity ahead has never been greater.”
Fourth Quarter 2024 Financial Results
Revenue was $4.0 million for the fourth quarter of 2024, a 10% decrease from $4.4 million for the corresponding prior year period, primarily due to lower instrument sales and no grant revenue recognized in the quarter. Product revenue for the fourth quarter of 2024 was $2.4 million, including $36 thousand of related party revenue, and consisted of sales of SP100 instruments and consumable kits. Service revenue was $1.6 million for the fourth quarter of 2024, including $353 thousand of related party revenue, and primarily consisted of revenue related to STAC service projects. Grant and other revenue was $51 thousand for the fourth quarter of 2024.
Gross profit was $2.0 million and gross margin was 51% for the fourth quarter of 2024.
Operating expenses were $25.5 million for the fourth quarter of 2024, including $6.0 million of stock-based compensation, an increase of 5% compared to $24.2 million for the corresponding prior year period, including $7.3 million of stock-based compensation. The increase in operating expenses was primarily driven by an increase in laboratory expenses.
Net loss was $21.7 million for the fourth quarter of 2024, compared to $17.8 million for the corresponding prior year period.
Full Year 2024 Financial Results
Revenue was $14.2 million for the full year 2024, a 15% decrease from $16.7 million for the corresponding prior year period, primarily due to lower product sales and no grant revenue recognized during the year. Product revenue for the full year 2024 was $10.2 million, including $1.5 million of related party revenue, and consisted of sales of SP100 instruments and consumable kits. Service revenue was $3.8 million for the full year 2024, including $828 thousand of related party revenue, and primarily consisted of revenue related to STAC service projects. Grant and other revenue was $223 thousand for the full year 2024.
Gross profit was $7.1 million and gross margin was 50% for the full year 2024.
Operating expenses were $107.2 million for the full year 2024, including $26.6 million of stock-based compensation, a decrease of 4% compared to $112.0 million for the corresponding prior year period, including $32.9 million of stock-based compensation.
Net loss was $86.6 million for the full year 2024, compared to $86.3 million for the corresponding prior year period.
Cash, cash equivalents and investments were approximately $300 million as of December 31, 2024.
2025 Guidance
Seer expects full year 2025 revenue to be in the range of $17 million to $18 million, representing growth of 24% at the midpoint over full year 2024.
Webcast Information
Seer will host a conference call to discuss the fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at https://investor.seer.bio. The webcast will be archived and available for replay for at least 90 days after the event.
About Seer
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s expectations for future results of operations and its financial position, business strategy, partnerships, adoption of our products and outlook for fiscal year 2025. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission (SEC) and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Contact:
Carrie Mendivil
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Patrick Schmidt
This email address is being protected from spambots. You need JavaScript enabled to view it.
| SEER, INC. Consolidated Statements of Operations (Unaudited) (in thousands, except share and per share amounts) | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Revenue: | |||||||||||||||
| Product | $ | 2,351 | $ | 2,669 | $ | 8,695 | $ | 8,506 | |||||||
| Service | 1,209 | 944 | 2,960 | 2,016 | |||||||||||
| Related party | 389 | 567 | 2,292 | 4,660 | |||||||||||
| Grant and other | 51 | 258 | 223 | 1,479 | |||||||||||
| Total revenue | 4,000 | 4,438 | 14,170 | 16,661 | |||||||||||
| Cost of revenue: | |||||||||||||||
| Product | 1,200 | 1,663 | 4,402 | 5,398 | |||||||||||
| Service | 566 | 390 | 1,465 | 685 | |||||||||||
| Related party | 61 | 204 | 712 | 1,430 | |||||||||||
| Grant and other | 148 | 180 | 536 | 642 | |||||||||||
| Total cost of revenue | 1,975 | 2,437 | 7,115 | 8,155 | |||||||||||
| Gross profit | 2,025 | 2,001 | 7,055 | 8,506 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | 12,619 | 11,165 | 50,585 | 53,019 | |||||||||||
| Selling, general and administrative | 12,894 | 13,068 | 56,571 | 58,950 | |||||||||||
| Total operating expenses | 25,513 | 24,233 | 107,156 | 111,969 | |||||||||||
| Loss from operations | (23,488 | ) | (22,232 | ) | (100,101 | ) | (103,463 | ) | |||||||
| Other income (expense): | |||||||||||||||
| Interest income | 3,565 | 4,720 | 16,666 | 17,764 | |||||||||||
| Loss on equity method investment | (1,788 | ) | — | (2,649 | ) | — | |||||||||
| Other income (expense) | 67 | (287 | ) | (417 | ) | (578 | ) | ||||||||
| Total other income | 1,844 | 4,433 | 13,600 | 17,186 | |||||||||||
| Loss before provision for income taxes | (21,644 | ) | (17,799 | ) | (86,501 | ) | (86,277 | ) | |||||||
| Provision for income taxes | 98 | — | 98 | — | |||||||||||
| Net loss | $ | (21,742 | ) | $ | (17,799 | ) | $ | (86,599 | ) | $ | (86,277 | ) | |||
| Net loss per share attributable to Class A and Class B common stockholders, basic and diluted | $ | (0.37 | ) | $ | (0.28 | ) | $ | (1.39 | ) | $ | (1.35 | ) | |||
| Weighted-average shares used in computing net loss per share attributable to Class A and Class B common stockholders, basic and diluted | 59,091,817 | 64,157,125 | 62,348,012 | 63,850,490 | |||||||||||
| SEER, INC. Consolidated Balance Sheets (Unaudited) (in thousands, except share and per share amounts) | ||||||||
| December 31, | ||||||||
| 2024 | 2023 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 40,753 | $ | 32,499 | ||||
| Short-term investments | 195,657 | 283,725 | ||||||
| Accounts receivable, net | 3,997 | 4,831 | ||||||
| Related party receivables | 379 | 559 | ||||||
| Other receivables | 1,853 | 1,326 | ||||||
| Inventory | 7,436 | 4,491 | ||||||
| Prepaid expenses and other current assets | 3,248 | 3,082 | ||||||
| Total current assets | 253,323 | 330,513 | ||||||
| Long-term investments | 63,103 | 56,858 | ||||||
| Operating lease right-of-use assets | 22,791 | 25,177 | ||||||
| Property and equipment, net | 18,575 | 22,193 | ||||||
| Restricted cash | 524 | 524 | ||||||
| Other assets | 8,281 | 1,004 | ||||||
| Total assets | $ | 366,597 | $ | 436,269 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 4,621 | $ | 1,370 | ||||
| Accrued expenses | 7,937 | 9,212 | ||||||
| Deferred revenue | 408 | 206 | ||||||
| Operating lease liabilities, current | 2,312 | 2,295 | ||||||
| Other current liabilities | 50 | 139 | ||||||
| Total current liabilities | 15,328 | 13,222 | ||||||
| Operating lease liabilities, net of current portion | 23,652 | 25,964 | ||||||
| Other noncurrent liabilities | 48 | 179 | ||||||
| Total liabilities | 39,028 | 39,365 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, $0.00001 par value; 5,000,000 shares authorized as of December 31, 2024 and 2023; zero shares issued and outstanding as of December 31, 2024 and 2023 | — | — | ||||||
| Class A common stock, $0.00001 par value; 94,000,000 shares authorized as of December 31, 2024 and 2023; 55,083,123 and 60,253,707 shares issued and outstanding as of December 31, 2024 and 2023, respectively | 1 | 1 | ||||||
| Class B common stock, $0.00001 par value; 6,000,000 shares authorized as of December 31, 2024 and 2023; 4,044,969 shares issued and outstanding as of December 31, 2024 and 2023 | — | — | ||||||
| Additional paid-in capital | 719,804 | 702,868 | ||||||
| Accumulated other comprehensive gain (loss) | 136 | (192 | ) | |||||
| Accumulated deficit | (392,372 | ) | (305,773 | ) | ||||
| Total stockholders’ equity | 327,569 | 396,904 | ||||||
| Total liabilities and stockholders’ equity | $ | 366,597 | $ | 436,269 | ||||
| Last Trade: | US$1.98 |
| Daily Change: | -0.12 -5.71 |
| Daily Volume: | 107,231 |
| Market Cap: | US$108.740M |
February 20, 2025 January 02, 2025 November 06, 2024 October 31, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
